CJC-1295 (no DAC)
A modified growth hormone releasing hormone analog with a shorter half-life than DAC-conjugated CJC-1295, allowing more physiological GH pulsing.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is CJC-1295 (no DAC)?
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) is a modified version of the first 29 amino acids of growth hormone releasing hormone. Unlike CJC-1295 with DAC which has an extended half-life of days, the no-DAC version has a half-life of about 30 minutes, allowing for more natural, pulsatile GH release patterns.
Why People Talk About It
Natural GH pulse optimization
ModerateBody composition improvement
EmergingEnhanced deep sleep
EmergingRecovery support
EmergingHow It Works
Mod GRF 1-29 mimics your body's natural growth hormone releasing hormone but is modified to last longer. It tells your pituitary gland to release growth hormone in natural pulses, especially when combined with a GHRP.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Not FDA-approved
- • Monitor IGF-1 levels
- • Use under clinician guidance
What We Don't Know
Long-term effects of sustained use for anti-aging purposes are not established through clinical trials.
Published Research
11 studiesGrowth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults
Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.
Tesamorelin, a human growth hormone releasing factor analogue.
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Related Peptides
CJC-1295
ModerateBeginnerA growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
Ipamorelin
ModerateBeginnerA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
Sermorelin
StrongBeginnerA growth hormone-releasing hormone analog that was previously FDA-approved for diagnosing GH deficiency in children.
GHR-2 (GHRP-2)
ModerateA synthetic growth hormone secretagogue that stimulates natural GH release, studied for body composition, recovery, and anti-aging.
Quick Facts
- Class
- GHRH Analog
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- Feb 2026
- Citations
- 11PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician